Sector Gamma AS Increases Stock Position in Elanco Animal Health Incorporated $ELAN

Key Points

• Sector Gamma AS has increased its holdings in Elanco Animal Health by 72.3% during the first quarter, bringing its total to 477,073 shares valued at approximately $5.01 million.
• Elanco Animal Health reported $0.26 earnings per share (EPS) for the last quarter, exceeding consensus estimates of $0.20, with a revenue increase of 4.8% year-over-year.
• Several analysts have upgraded Elanco Animal Health's stock rating, with a consensus rating of "Moderate Buy" and an average price target set at $17.33.

Sector Gamma AS lifted its stake in shares of Elanco Animal Health Incorporated (NYSE:ELAN - Free Report) by 72.3% during the 1st quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm owned 477,073 shares of the company's stock after acquiring an additional 200,166 shares during the period. Elanco Animal Health accounts for about 1.6% of Sector Gamma AS's investment portfolio, making the stock its 22nd largest position. Sector Gamma AS owned 0.10% of Elanco Animal Health worth $5,009,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Several other institutional investors and hedge funds also recently modified their holdings of ELAN. Dimensional Fund Advisors LP boosted its position in Elanco Animal Health by 14.3% during the 1st quarter. Dimensional Fund Advisors LP now owns 20,464,727 shares of the company's stock worth $214,875,000 after acquiring an additional 2,563,740 shares during the period. Russell Investments Group Ltd. boosted its stake in Elanco Animal Health by 695.7% during the 1st quarter. Russell Investments Group Ltd. now owns 201,389 shares of the company's stock valued at $2,115,000 after purchasing an additional 176,078 shares during the period. Callan Family Office LLC grew its holdings in shares of Elanco Animal Health by 33.5% during the 1st quarter. Callan Family Office LLC now owns 49,024 shares of the company's stock worth $515,000 after purchasing an additional 12,304 shares in the last quarter. HighTower Advisors LLC grew its holdings in shares of Elanco Animal Health by 7.0% in the 1st quarter. HighTower Advisors LLC now owns 12,445 shares of the company's stock worth $131,000 after purchasing an additional 810 shares during the last quarter. Finally, Nuveen LLC acquired a new stake in Elanco Animal Health in the 1st quarter valued at about $115,212,000. Hedge funds and other institutional investors own 97.48% of the company's stock.

Elanco Animal Health Trading Down 1.0%

NYSE:ELAN traded down $0.1750 during mid-day trading on Tuesday, reaching $17.5250. 5,552,694 shares of the company's stock traded hands, compared to its average volume of 5,429,805. The company has a 50 day moving average price of $14.81 and a 200-day moving average price of $12.31. The firm has a market capitalization of $8.71 billion, a price-to-earnings ratio of 20.38, a PEG ratio of 3.33 and a beta of 1.66. The company has a debt-to-equity ratio of 0.61, a current ratio of 2.60 and a quick ratio of 1.40. Elanco Animal Health Incorporated has a 12-month low of $8.02 and a 12-month high of $18.08.

Elanco Animal Health (NYSE:ELAN - Get Free Report) last issued its quarterly earnings data on Thursday, August 7th. The company reported $0.26 earnings per share for the quarter, topping analysts' consensus estimates of $0.20 by $0.06. The firm had revenue of $1.24 billion for the quarter, compared to analyst estimates of $1.19 billion. Elanco Animal Health had a return on equity of 7.04% and a net margin of 9.68%.The business's quarterly revenue was up 4.8% compared to the same quarter last year. During the same period last year, the company earned $0.30 EPS. Elanco Animal Health has set its Q3 2025 guidance at 0.120-0.160 EPS. FY 2025 guidance at 0.850-0.91 EPS. On average, sell-side analysts predict that Elanco Animal Health Incorporated will post 0.91 earnings per share for the current year.

Analysts Set New Price Targets

A number of analysts recently weighed in on the stock. UBS Group increased their price target on shares of Elanco Animal Health from $18.00 to $19.00 and gave the company a "buy" rating in a research report on Friday, August 8th. William Blair raised Elanco Animal Health from a "market perform" rating to an "outperform" rating in a research report on Thursday, June 26th. Leerink Partners upgraded Elanco Animal Health from a "market perform" rating to an "outperform" rating and set a $18.00 price target for the company in a research note on Thursday, July 17th. Wall Street Zen raised shares of Elanco Animal Health from a "hold" rating to a "buy" rating in a research note on Saturday, July 5th. Finally, Stifel Nicolaus lifted their price target on shares of Elanco Animal Health from $16.00 to $17.00 and gave the company a "buy" rating in a research report on Wednesday, July 2nd. One equities research analyst has rated the stock with a Strong Buy rating, five have given a Buy rating and two have issued a Hold rating to the stock. Based on data from MarketBeat.com, the company currently has an average rating of "Moderate Buy" and an average target price of $17.33.

Elanco Animal Health Company Profile

Elanco Animal Health Incorporated, an animal health company, innovates, develops, manufactures, and markets products for pets and farm animals. It offers pet health disease prevention products, such as parasiticide and vaccine products that protect pets from worms, fleas, and ticks under the Seresto, Advantage, Advantix, and Advocate brands; pet health therapeutics for pain, osteoarthritis, ear infections, cardiovascular, and dermatology indications in canines and felines under the Galliprant and Claro brands; vaccines, antibiotics, parasiticides, and other products for use in poultry and aquaculture production, as well as nutritional health products, including enzymes, probiotics, and prebiotics; and a range of vaccines, antibiotics, implants, parasiticides, and other products used in ruminant and swine production under the Rumensin and Baytril brands.